Lian Yu-Fei, Liu Dan-Qing, Wang Hui
Department of Radiology, Affiliated Beijing Chaoyang Hospital of Capital Medical University (Shijingshan Campus) Beijing 100043, The People's Republic of China.
Institute of Genetics and Developmental Biology, Chinese Academy of Sciences Beijing 100101, The People's Republic of China.
Am J Transl Res. 2025 Mar 15;17(3):1554-1567. doi: 10.62347/BMWY7899. eCollection 2025.
This meta-analysis aimed to evaluate the combined effectiveness of Magnetic Resonance Imaging (MRI) and mammography in detecting breast cancer in women with dense breasts.
A comprehensive search was conducted across PubMed, Web of Science, and EMBASE databases up to December 31, 2023, to identify relevant studies. Studies focusing on breast cancer detection in women with dense breast tissue and providing data on the sensitivity, specificity, or positive predictive value of combined MRI and mammography screening, or the use of MRI following a negative mammogram, were included. The meta-analysis was conducted using Stata 15.0, and study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool.
Ten studies, involving 51,602 participants, were included in the meta-analysis. The combined use of MRI and mammography for breast cancer detection in women with dense breasts yielded a pooled sensitivity of 0.87 (95% CI: 0.79-0.92), specificity of 0.95 (95% CI: 0.89-0.97), positive likelihood ratio of 2.55 (95% CI: 1.45-4.46), negative likelihood ratio of 0.11 (95% CI: 0.07-0.17), diagnostic score of 3.18 (95% CI: 2.35-4.02), and diagnostic ratio of 24.14 (95% CI: 10.44-55.81), and an area under the Summary Receiver Operating Characteristic curve of 0.97 (95% CI: 0.95-0.98).
This meta-analysis demonstrated that the combination of MRI and mammography enhanced breast cancer detection in women with dense breasts. This synergistic approach significantly improves detection sensitivity in this high-risk group.
本荟萃分析旨在评估磁共振成像(MRI)和乳腺钼靶联合检测致密型乳腺女性乳腺癌的综合有效性。
截至2023年12月31日,对PubMed、科学网和EMBASE数据库进行全面检索,以识别相关研究。纳入关注致密型乳腺组织女性乳腺癌检测,并提供MRI和乳腺钼靶联合筛查的敏感性、特异性或阳性预测值数据,或乳腺钼靶检查阴性后使用MRI的数据的研究。使用Stata 15.0进行荟萃分析,并使用诊断准确性研究质量评估-2(QUADAS-2)工具评估研究质量。
荟萃分析纳入了10项研究,涉及51602名参与者。MRI和乳腺钼靶联合用于致密型乳腺女性乳腺癌检测的合并敏感性为0.87(95%CI:0.79-0.92),特异性为0.95(95%CI:0.89-0.97),阳性似然比为2.55(95%CI:1.45-4.46),阴性似然比为0.11(95%CI:0.07-0.17),诊断评分3.18(95%CI:2.35-4.02),诊断比24.14(95%CI:10.44-55.81),汇总接受者操作特征曲线下面积为0.97(95%CI:0.95-0.98)。
本荟萃分析表明,MRI和乳腺钼靶联合可提高致密型乳腺女性乳腺癌的检测率。这种协同方法显著提高了该高危人群的检测敏感性。